CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have earned a consensus rating of “Hold” from the nineteen ratings firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $71.50.

CRSP has been the topic of a number of recent analyst reports. Piper Sandler reissued an “overweight” rating and issued a $105.00 price target on shares of CRISPR Therapeutics in a report on Friday, June 27th. HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, September 23rd. Royal Bank Of Canada upped their price target on CRISPR Therapeutics from $38.00 to $42.00 and gave the company a “sector perform” rating in a research report on Tuesday, August 5th. Chardan Capital reiterated a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, August 5th. Finally, JMP Securities reissued a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research note on Friday, June 27th.

Insider Transactions at CRISPR Therapeutics

In related news, Director Simeon George acquired 989,812 shares of the stock in a transaction on Wednesday, July 16th. The stock was acquired at an average cost of $52.03 per share, for a total transaction of $51,499,918.36. Following the completion of the acquisition, the director directly owned 1,730,179 shares of the company’s stock, valued at approximately $90,021,213.37. This represents a 133.69% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Atlantic Union Bankshares Corp bought a new stake in shares of CRISPR Therapeutics during the 2nd quarter valued at $33,000. SVB Wealth LLC bought a new stake in CRISPR Therapeutics during the first quarter worth about $25,000. Strategic Wealth Investment Group LLC purchased a new stake in CRISPR Therapeutics in the second quarter worth about $36,000. Costello Asset Management INC bought a new position in shares of CRISPR Therapeutics during the first quarter valued at approximately $27,000. Finally, IFP Advisors Inc increased its stake in shares of CRISPR Therapeutics by 24.6% during the second quarter. IFP Advisors Inc now owns 916 shares of the company’s stock valued at $45,000 after purchasing an additional 181 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Stock Performance

Shares of CRSP stock opened at $67.74 on Monday. The company has a market capitalization of $6.16 billion, a P/E ratio of -12.48 and a beta of 1.84. CRISPR Therapeutics has a fifty-two week low of $30.04 and a fifty-two week high of $73.95. The stock has a 50 day moving average price of $57.69 and a two-hundred day moving average price of $47.85.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.18. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The firm had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $6.44 million. During the same quarter last year, the business earned ($1.49) earnings per share. The business’s revenue was up 72.5% on a year-over-year basis. As a group, equities analysts predict that CRISPR Therapeutics will post -5.16 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.